FRANK L. ENGEL, M.D.; CLARENCE COHN, M.D.; LOUIS J. SOFFER, M.D.
Since the original reports by Levy-Simpson1 and Thorn2, 3, 4 on the use of desoxycorticosterone acetate in the treatment of Addison's disease, many further reports have appeared confirming its value and pointing out its limitations and toxic effects resulting from overdosage.5, 6, 7 In 1939 an advance in therapy was made by Thorn and his co-workers8, 9 who utilized the technic of Deanesly and Parkes10 and maintained adrenalectomized dogs and patients with Addison's disease in good condition by implantation of pellets of crystalline desoxycorticosterone acetate subcutaneously. By this method a slow and steady release of hormone, calculated at about 0.2
ENGEL FL, COHN C, SOFFER LJ. A FURTHER REPORT ON THE TREATMENT OF ADDISON'S DISEASE WITH DESOXYCORTICOSTERONE ACETATE BY INTRAMUSCULAR INJECTIONS, SUBCUTANEOUS IMPLANTATION OF PELLETS, AND SUBLINGUAL ADMINISTRATION(A FURTHER REPORT ON THE TREATMENT OF ADDISON'S DISEASE WITH DESOXYCORTICOSTERONE ACETATE BY INTRAMUSCULAR INJECTIONS, SUBCUTANEOUS IMPLANTATION OF PELLETS, AND SUBLINGUAL ADMINISTRATION*). Ann Intern Med. 1942;17:585–603. doi: 10.7326/0003-4819-17-4-585
Download citation file:
Published: Ann Intern Med. 1942;17(4):585-603.
Adrenal Disorders, Endocrine and Metabolism.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use